Paternity Following Treatment for Testicular Cancer

Brydøy, Marianne; Fosså, Sophie D.; Klepp, Olbjørn; Bremnes, Roy M.; Wist, Erik; Wentzel‐Larsen, Tore; Dahl, Olav

doi:10.1093/jnci/dji339

Cited by 242 publications

(194 citation statements)

References 53 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…Secondly, we relate our end point to the number of patients reported having attempted parenthood. For male HLSs, the proportion of 45% who reported attempted parenthood is comparable to that observed in two studies of testicular cancer survivors (TCSs), where 31 and 39%, respectively, had tried to father a child following treatment (Rieker et al, 1990;Brydoy et al, 2005).…”

Section: Discussionsupporting

confidence: 67%

Post-treatment parenthood in Hodgkin's lymphoma survivors

Kiserud

Fosså²,

Holte³

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

Attempted and achieved post-treatment parenthood, with or without use of assisted reproduction techniques (ARTs), was assessed in Hodgkin's lymphoma survivors treated from 1971 -1998, aged below 50 (females) or 65 (males) at diagnosis, aged 18 to 75 at survey. Four treatment groups were constructed: radiotherapy only, low -, medium -and high gonadotoxic chemotherapy (with or without radiotherapy in the three chemotherapy groups). Using Kaplan -Meier estimates, log-rank tests and Cox regression analyses, factors influencing post-treatment parenthood were investigated, with birth of the first child after treatment as the end point. Fortyfive per cent (120/269) of males and 50% (91/184) of females reported attempted post-treatment parenthood. Of these, 76 (63%) males and 68 (75%) females had a child without use of ARTs. In addition 10 males and one female achieved post-treatment parenthood with use of ARTs. Treatment group was significantly associated with post-treatment parenthood, with highest probabilities after radiotherapy only and low gonadotoxic chemotherapy. In univariate analyses, age at diagnosis was a significant factor related to post-treatment parenthood in females.

show abstract

Section: Discussionsupporting

confidence: 67%

Post-treatment parenthood in Hodgkin's lymphoma survivors

Kiserud

Fosså²,

Holte³

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Chemotherapy has the greatest impact on fertility, followed by radiotherapy and retroperitoneal lymph node dissection (30,31). Fosså et al (28) reported that the paternity rate in 1,814 testicular cancer survivors was 71% and the duration from diagnosis until the birth of the first child after diagnosis was 6.6 years (28).…”

Section: Discussionmentioning

confidence: 99%

Testicular germ cell tumor: Short and long-term side effects of treatment among survivors

Gil

Sideris

Aoun

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Long-term prognosis of germ cell tumor (GCT) types is excellent, however, treatment is associated with non-negligible complication rates and a negative impact on quality of life. The present study described treatment results in terms of survival, both short and long-term toxicity, and paternity rates in a cohort of patients treated at Jules Bordet Institute, University ULB of Brussels (Brussels, Belgium). The present study analyzed the data of a cohort of patients with GCT types. Pre-operative patient and tumor characteristics were described. Performance status, pulmonary function tests and renal clearance prior to chemotherapy were noted. Chemotherapeutic regimens and their associated toxicities were analyzed. The duration to event-free, cancer-specific and overall survivals were estimated using Kaplan-Meier curves. A total of 115 patients (median age, 31-years-old) were treated for a GCT at Jules Bordet Institute. At a median follow-up of 6-years, 11 (10%) patients had relapsed and 2 (2%) developed a second malignant neoplasm. At the final follow-up, 97 (89%) and 6 (5.5%) patients exhibited complete and partial remission, respectively. A total of 6% of patients exhibited a progressive disease. In terms of short-term toxicity, 11% of patients presented with febrile neutropenia. The 10-year overall survival rate and relapse-free survival rate were 93.4 and 89.8%, respectively. The paternity rate post-treatment was 27%. Testicular GCT survivors suffered from short-and long-term treatment-associated side effects on both a physical and psychological level. A long-term close follow-up is necessary in order to assist the patient with these treatment-induced complications.

show abstract

“…For example, until recently treatment of testicular cancer and Hodgkin disease had strong gonadotoxic side effects. The discovery of cisplatin-and non-alkylating agent-based therapies to treat these diseases offers not only a high cure rate, but also a high probability that patients spontaneously regain their fertility (38,39). Although the protocols are under constant review, presently it is unlikely that the treatment strategies for the most malignant diseases can be improved upon without diminishing their efficacy.…”

Section: New Clinically Relevant Technologies For Preservation Of Fermentioning

confidence: 99%

Clinical Potential and Putative Risks of Fertility Preservation in Children Utilizing Gonadal Tissue or Germline Stem Cells

et al. 2006

View full text Add to dashboard Cite

show abstract

Paternity Following Treatment for Testicular Cancer

Abstract: Although the overall paternity rate after treatment for testicular cancer was high, the ability to conceive and the time to conception reflected the intensity of treatment. These data may help inform patients about their future ability to father biological children.

Cited by 242 publications

References 53 publications

Post-treatment parenthood in Hodgkin's lymphoma survivors

Post-treatment parenthood in Hodgkin's lymphoma survivors

Testicular germ cell tumor: Short and long-term side effects of treatment among survivors

Clinical Potential and Putative Risks of Fertility Preservation in Children Utilizing Gonadal Tissue or Germline Stem Cells

Contact Info

Product

Resources

About